Biocartis Group NV, a pioneering molecular diagnostics company, is headquartered in Belgium (BE) and operates across Europe and beyond. Founded in 2007, Biocartis has established itself in the healthcare industry, focusing on innovative solutions for cancer diagnostics. The company is renowned for its Idylla™ platform, which offers rapid, accurate testing for various cancers, setting it apart with its ease of use and speed. Biocartis has achieved significant milestones, including partnerships with leading pharmaceutical companies and regulatory approvals for its products, solidifying its position in the market. With a commitment to advancing personalised medicine, Biocartis continues to enhance patient care through its cutting-edge diagnostic solutions, making it a key player in the molecular diagnostics landscape.
How does Biocartis Group NV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Biocartis Group NV's score of 29 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biocartis Group NV, headquartered in Belgium (BE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Biocartis may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As such, the company does not inherit emissions data from any parent or related organizations, and all information is derived solely from its own reporting.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biocartis Group NV has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

